GNAS and hepatocellular carcinoma: To detect and validate the autoantibody response to GNAS in patients at different stages of transition from chronic liver disease to HCC, a large-scale sample set (n = 912) was established to further evaluate the possibility of autoantibody to GNAS as a serum biomarker for early detection of HCC.